Optimising Health-Related Quality of Life in Children With Osteogenesis Imperfecta

被引:1
作者
Hill, Claire L. [1 ]
Ford, Davina [1 ]
Baker, Jill [1 ]
机构
[1] Sheffield Childrens NHS Fdn Trust, Sheffield, England
关键词
Osteogenesis imperfecta; Children; Health-related quality of life; INTRAVENOUS PAMIDRONATE TREATMENT; BISPHOSPHONATE TREATMENT; PHYSICAL-ACTIVITY; ZOLEDRONIC ACID; MUSCLE STRENGTH; FOLLOW-UP; ADOLESCENTS; PAIN; IMPAIRMENT; DISABILITY;
D O I
10.1007/s00223-024-01205-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis Imperfecta is a rare, hereditary bone condition with an incidence of 1/15,000-20,000. Symptoms include bone fragility, long bone deformity, scoliosis, hypermobility, alongside secondary features such as short stature, basilar invagination, pulmonary and cardiac complications, hearing loss, dentinogenesis imperfecta and malocclusion. Osteogenesis Imperfecta can have a large impact on the child and their family; this impact starts immediately after diagnosis. Fractures, pain, immobility, hospital admissions and the need for equipment and adaptations all influence the health-related quality of life of the individual and their family. This narrative review article aims to examine the impact the diagnosis and management of osteogenesis imperfecta has on the health-related quality of life of a child. It will touch on the effect this may have on the quality of life of their wider family and friends and identify strategies to optimise health-related quality of life in this population. Optimising health-related quality of life in children with Osteogenesis Imperfecta is often a complicated, multifaceted journey that involves the child, their extended family, school, extracurricular staff and numerous health professionals.
引用
收藏
页码:828 / 846
页数:19
相关论文
共 117 条
[81]  
Osteogenesis Imperfecta Foundation, 2022, SOCIAL EMOTIONAL ISS
[82]   Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study [J].
Otaify, G. A. ;
Aglan, M. S. ;
Ibrahim, M. M. ;
Elnashar, M. ;
El Banna, R. A. S. ;
Temtamy, S. A. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (01) :81-92
[83]   Health-Related Quality of Life of Young People With and Without Chronic Conditions [J].
Pinquart, Martin .
JOURNAL OF PEDIATRIC PSYCHOLOGY, 2020, 45 (07) :780-792
[84]   Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age [J].
Plotkin, H ;
Rauch, F ;
Bishop, NJ ;
Montpetit, K ;
Ruck-Gibis, J ;
Travers, R ;
Glorieux, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) :1846-1850
[85]  
Pouliot-Laforte A, 2015, J MUSCULOSKEL NEURON, V15, P171
[86]   Static Postural Control in Youth With Osteogenesis Imperfecta Type I [J].
Pouliot-Laforte, Annie ;
Lemay, Martin ;
Rauch, Frank ;
Veilleux, Louis-Nicolas .
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2017, 98 (10) :1948-1954
[87]   Exploring pain interference and self-perceived health status in children with osteogenesis imperfecta-a cross-sectional study [J].
Provenzano, Anna Hallin ;
Astrom, Eva ;
Lowing, Kristina .
BMC MUSCULOSKELETAL DISORDERS, 2022, 23 (01)
[88]   Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review [J].
Rijks, Ester B. G. ;
Bongers, Bart C. ;
Vlemmix, Marloes J. G. ;
Boot, Annemieke M. ;
van Dijk, Atty T. H. ;
Sakkers, Ralph J. B. ;
van Brussel, Marco .
HORMONE RESEARCH IN PAEDIATRICS, 2015, 84 (01) :26-42
[89]  
Celin MR, 2016, ARCH ARGENT PEDIATR, V114, P248, DOI [10.5546/aap.2016.eng.248, 10.5546/aap.2016.248]
[90]   Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year [J].
Ruck, Joanne ;
Dahan-Oliel, Noemi ;
Montpetit, Kathleen ;
Rauch, Frank ;
Fassier, Francois .
JOURNAL OF CHILDRENS ORTHOPAEDICS, 2011, 5 (03) :217-224